Artelo Biosciences, Inc.
ARTLNASDAQHealthcareBiotechnology
Previous close
$0.692
−$0.0204 · -2.86%
ARTL company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
28
Expensive
Momentum
17
Strong Down
Sentiment
54
Mixed
Risk resilience
37
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteArtelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Gregory D. Gorgas
- Listed since
- Jun 21, 2019
- Employees
- 7
Market position
Day range
Current $0.692
52-week range
Current $0.692
- Open
- $0.72
- Previous close
- $0.7124
- Volume
- 108.9K
- 0.08× average
- Average volume
- 1.3M
- Average daily volume
- Market cap
- 2.41M USD
- Beta
- -0.07
- Market reference 1
- 50-day average
- $0.9914
- -30.20% below average
- 200-day average
- $3.5556
- -80.54% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 2.95M USD
- P/E (TTM)
- -0.08×
- P/B (TTM)
- 0.38×
- P/S (TTM)
- 0×
- EV / EBITDA
- -0.24×
- Earnings yield
- -447.98%
- Free cash flow yield
- -296.36%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- 1012.50%
- Return on assets
- -459.80%
- Return on invested capital
- 1919.87%
Financial health
- Debt / equity
- 0.01×
- Current ratio
- 0.17×
- Altman Z-score
- -19.45
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 5.42M USD | 5.99M USD | 5.7M USD | 4.32M USD | 2.84M USD |
| Selling, general, and administrative | 5.98M USD | 4.12M USD | 4.23M USD | 5.96M USD | 4.6M USD |
| Operating expenses | 11.4M USD | 10.11M USD | 9.93M USD | 10.29M USD | 7.44M USD |
| Interest income | — | — | — | 2K USD | 2K USD |
| Interest expense | 194K USD | — | — | 5K USD | — |
| Depreciation and amortization | 146K USD | — | — | — | — |
| Operating income | −11.4M USD | −10.11M USD | −9.93M USD | −10.29M USD | −7.44M USD |
| Net income | −12.88M USD | −9.83M USD | −9.29M USD | −10.08M USD | −7.44M USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest fiscal-year EPS
- -5.47
- FY2025
- Latest fiscal-year revenue
- 0 USD
- FY2025
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
4 ratingsLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Recent analyst actions
ARTL news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 10, 2026 | 1:3 | — | — |
Stock split | Jun 13, 2025 | 1:6 | — | — |
Stock split | Aug 10, 2022 | 1:15 | — | — |
Stock split | Jun 21, 2019 | 1:8 | — | — |
Effective Mar 10, 2026
1:3
Effective Jun 13, 2025
1:6
Effective Aug 10, 2022
1:15
Effective Jun 21, 2019
1:8
ARTL peers
ETFs holding ARTL
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research ARTLresearch.disclaimer